Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Erin Schwartz"'
Autor:
Bonnie Addario, Jan Geissler, Marcia K. Horn, Linda U. Krebs, Deborah Maskens, Kathy Oliver, Ananda Plate, Erin Schwartz, Nicole Willmarth
Publikováno v:
Health Expectations, Vol 23, Iss 1, Pp 41-51 (2020)
Abstract Context Patient‐reported outcomes (PROs) are used in parallel with clinical evidence to inform decisions made by industry, clinicians, regulators, health technology assessment bodies and other health‐care decision‐makers. In addition,
Externí odkaz:
https://doaj.org/article/905a28ee91614c4eb6dd98134b36a837
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-3 (2018)
Externí odkaz:
https://doaj.org/article/e660de06b9184613a3e98f2ab0297394
Autor:
Heather Wilkins, Sharon J. Manley, Xiaowan Wang, Blaise W. Menta, Scott Koppel, Rebecca Bothwell, Annette M. Becker, Heidi Anderson, Erin Schwartz, Jeffrey M. Burns, Russell H. Swerdlow
Background:This study examined the impact of APOE ε4 on blood cell bioenergetics. Prior studies have shown systemic alterations in blood cells from APOE ε4 carriers.Methods:Platelet mitochondria cytochrome oxidase (COX) and citrate synthase (CS) Vm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abef0de4ff2cb5a44e03f33bbdec4e01
https://doi.org/10.21203/rs.3.rs-37441/v1
https://doi.org/10.21203/rs.3.rs-37441/v1
Autor:
Annette M. Becker, Heather M. Wilkins, Erica Sherry, Xiaowan Wang, Heidi Anderson, Blaise W. Menta, Scott J. Koppel, Russell H. Swerdlow, Rebecca Bothwell, Erin Schwartz, Jeffrey M. Burns
Publikováno v:
Alzheimer's & Dementia. 15:P667-P668
Autor:
Erin Schwartz
Publikováno v:
African Arts. 52:95-96
Autor:
Erin Schwartz
Publikováno v:
The International Journal of the Arts in Society: Annual Review. 2:7-12
Autor:
Erin Schwartz
Publikováno v:
The International Journal of the Humanities: Annual Review. 4:201-210
Autor:
Mislen Bauer, Christine Haller, Raymond Y. Wang, Chester B. Whitley, Emil D. Kakkis, Erin Schwartz, Karen Jacobs, Wenjie Song, Paul Harmatz
Publikováno v:
Molecular Genetics and Metabolism. 120:S63
Publikováno v:
Cancer Research. 73:4648-4648
Romidepsin is a class I selective HDAC inhibitor approved for the treatment of cutaneous T cell lymphoma (CTCL) and peripheral T cell lymphoma (PTCL) in the US. In contrast to the 30% response rate to romidepsin in these malignancies, only rare respo